Oragenics appoints Dr John Bonfiglio
This article was originally published in Scrip
Oragenics, a biopharmaceutical company has appointed Dr John Bonfiglio president and CEO, as well as appointing him to the board of directors. Dr Bonfiglio most recently served as president, CEO and director for Transdel Pharmaceuticals. He has also been CEO of Argos Therapeutics, the Immune Response Corporation and Peregrine Pharmaceuticals.